Cantor Fitzgerald Analysts Give TherapeuticsMD (TXMD) a $27.00 Price Target

Cantor Fitzgerald set a $27.00 price objective on TherapeuticsMD (NASDAQ:TXMD) in a research report sent to investors on Wednesday morning. The brokerage currently has a buy rating on the stock.

Several other research firms also recently weighed in on TXMD. Zacks Investment Research downgraded TherapeuticsMD from a hold rating to a sell rating in a report on Friday, August 17th. Oppenheimer set a $14.00 target price on TherapeuticsMD and gave the company a buy rating in a report on Wednesday, September 26th. ValuEngine raised TherapeuticsMD from a hold rating to a buy rating in a report on Friday, September 21st. Finally, BidaskClub cut TherapeuticsMD from a hold rating to a sell rating in a research report on Thursday, November 1st. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and five have given a buy rating to the company. The stock presently has an average rating of Buy and an average price target of $13.45.

Shares of TherapeuticsMD stock traded down $0.04 on Wednesday, hitting $4.93. The stock had a trading volume of 1,868,728 shares, compared to its average volume of 3,371,973. TherapeuticsMD has a 52-week low of $4.30 and a 52-week high of $7.66. The company has a debt-to-equity ratio of 0.94, a current ratio of 7.88 and a quick ratio of 7.79.

TherapeuticsMD (NASDAQ:TXMD) last posted its earnings results on Wednesday, November 7th. The company reported ($0.16) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.22) by $0.06. TherapeuticsMD had a negative return on equity of 109.28% and a negative net margin of 757.59%. The business had revenue of $3.47 million during the quarter, compared to the consensus estimate of $4.43 million. During the same period in the previous year, the business earned ($0.07) EPS. The business’s quarterly revenue was down 21.5% on a year-over-year basis. On average, research analysts anticipate that TherapeuticsMD will post -0.63 earnings per share for the current fiscal year.

In related news, insider John C.K. Iv Milligan sold 250,000 shares of the business’s stock in a transaction dated Tuesday, September 11th. The stock was sold at an average price of $6.10, for a total value of $1,525,000.00. Following the transaction, the insider now owns 1,597,419 shares in the company, valued at approximately $9,744,255.90. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Robert G. Finizio sold 184,000 shares of the business’s stock in a transaction dated Friday, September 7th. The shares were sold at an average price of $6.24, for a total value of $1,148,160.00. Following the completion of the transaction, the chief executive officer now owns 18,485,559 shares in the company, valued at approximately $115,349,888.16. The disclosure for this sale can be found here. Insiders sold a total of 2,158,800 shares of company stock worth $12,946,562 in the last 90 days. 22.85% of the stock is currently owned by insiders.

Hedge funds have recently modified their holdings of the stock. OppenheimerFunds Inc. increased its position in TherapeuticsMD by 17.4% in the 2nd quarter. OppenheimerFunds Inc. now owns 1,932,439 shares of the company’s stock valued at $12,058,000 after acquiring an additional 286,123 shares during the period. BlackRock Inc. increased its position in TherapeuticsMD by 4.4% in the 2nd quarter. BlackRock Inc. now owns 14,533,524 shares of the company’s stock valued at $90,690,000 after acquiring an additional 608,470 shares during the period. Xact Kapitalforvaltning AB increased its position in TherapeuticsMD by 96.3% in the 1st quarter. Xact Kapitalforvaltning AB now owns 31,800 shares of the company’s stock valued at $155,000 after acquiring an additional 15,600 shares during the period. Public Employees Retirement Association of Colorado increased its position in TherapeuticsMD by 2,545.7% in the 2nd quarter. Public Employees Retirement Association of Colorado now owns 1,071,500 shares of the company’s stock valued at $6,686,000 after acquiring an additional 1,031,000 shares during the period. Finally, Twin Focus Capital Partners LLC acquired a new position in TherapeuticsMD in the 2nd quarter valued at about $187,000. Hedge funds and other institutional investors own 66.20% of the company’s stock.

TherapeuticsMD Company Profile

TherapeuticsMD, Inc operates as a women's health care product company. Its pipeline of hormone therapy drug candidates include TX-001HR, a combination of estradiol and progesterone drug candidate under clinical trials for the treatment of moderate to severe vasomotor symptoms due to menopause; TX-002HR, a natural progesterone formulation for the treatment of secondary amenorrhea without the potentially allergenic component of peanut oil; and TX-004HR, an applicator-free vaginal estradiol softgel drug candidate for the treatment of moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy in post-menopausal women with vaginal linings that do not receive enough estrogen.

Read More: Understanding Relative Strength Index

Analyst Recommendations for TherapeuticsMD (NASDAQ:TXMD)

Receive News & Ratings for TherapeuticsMD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply